AAPL   329.73 (+2.30%)
MSFT   186.09 (+1.73%)
GOOGL   1,440.26 (+1.84%)
AMZN   2,474.67 (+0.57%)
NVDA   357.24 (+1.88%)
CGC   16.79 (+0.96%)
BABA   219.53 (+0.68%)
MU   54.36 (+6.13%)
GE   8.12 (+4.91%)
TSLA   876.96 (+1.46%)
AMD   53.27 (+1.22%)
ACB   13.90 (-2.32%)
GILD   77.04 (-0.64%)
NFLX   417.02 (+0.65%)
AAPL   329.73 (+2.30%)
MSFT   186.09 (+1.73%)
GOOGL   1,440.26 (+1.84%)
AMZN   2,474.67 (+0.57%)
NVDA   357.24 (+1.88%)
CGC   16.79 (+0.96%)
BABA   219.53 (+0.68%)
MU   54.36 (+6.13%)
GE   8.12 (+4.91%)
TSLA   876.96 (+1.46%)
AMD   53.27 (+1.22%)
ACB   13.90 (-2.32%)
GILD   77.04 (-0.64%)
NFLX   417.02 (+0.65%)
AAPL   329.73 (+2.30%)
MSFT   186.09 (+1.73%)
GOOGL   1,440.26 (+1.84%)
AMZN   2,474.67 (+0.57%)
NVDA   357.24 (+1.88%)
CGC   16.79 (+0.96%)
BABA   219.53 (+0.68%)
MU   54.36 (+6.13%)
GE   8.12 (+4.91%)
TSLA   876.96 (+1.46%)
AMD   53.27 (+1.22%)
ACB   13.90 (-2.32%)
GILD   77.04 (-0.64%)
NFLX   417.02 (+0.65%)
AAPL   329.73 (+2.30%)
MSFT   186.09 (+1.73%)
GOOGL   1,440.26 (+1.84%)
AMZN   2,474.67 (+0.57%)
NVDA   357.24 (+1.88%)
CGC   16.79 (+0.96%)
BABA   219.53 (+0.68%)
MU   54.36 (+6.13%)
GE   8.12 (+4.91%)
TSLA   876.96 (+1.46%)
AMD   53.27 (+1.22%)
ACB   13.90 (-2.32%)
GILD   77.04 (-0.64%)
NFLX   417.02 (+0.65%)
Log in

NYSE:TAROTaro Pharmaceutical Industries Stock Price, Forecast & News

$68.03
+0.07 (+0.10 %)
(As of 06/5/2020 01:00 PM ET)
Add
Compare
Today's Range
$67.88
Now: $68.03
$68.84
50-Day Range
$64.72
MA: $67.85
$70.16
52-Week Range
$56.07
Now: $68.03
$99.69
Volume3,036 shs
Average Volume31,920 shs
Market Capitalization$2.60 billion
P/E Ratio10.70
Dividend YieldN/A
Beta0.79
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. The company sells and distributes its products principally to drug industry wholesalers, drug store chains, mass merchandisers, healthcare institutions, and private pharmacies. The company was founded in 1959 and is based in Haifa Bay, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Zrt.
Read More
Taro Pharmaceutical Industries logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.39 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone972-4847-5700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$644.77 million
Cash Flow$6.92 per share
Book Value$55.15 per share

Profitability

Net Income$244.24 million

Miscellaneous

Employees1,464
Market Cap$2.60 billion
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable

Receive TARO News and Ratings via Email

Sign-up to receive the latest news and ratings for TARO and its competitors with MarketBeat's FREE daily newsletter.

Taro Pharmaceutical Industries (NYSE:TARO) Frequently Asked Questions

How has Taro Pharmaceutical Industries' stock been impacted by COVID-19 (Coronavirus)?

Taro Pharmaceutical Industries' stock was trading at $64.44 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TARO shares have increased by 5.6% and is now trading at $68.03. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Taro Pharmaceutical Industries?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Taro Pharmaceutical Industries in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Taro Pharmaceutical Industries.

When is Taro Pharmaceutical Industries' next earnings date?

Taro Pharmaceutical Industries is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Taro Pharmaceutical Industries.

How were Taro Pharmaceutical Industries' earnings last quarter?

Taro Pharmaceutical Industries Ltd. (NYSE:TARO) released its quarterly earnings results on Tuesday, May, 19th. The company reported $1.42 earnings per share for the quarter, missing the Zacks' consensus estimate of $1.53 by $0.11. The firm had revenue of $174.94 million for the quarter, compared to analyst estimates of $168.25 million. Taro Pharmaceutical Industries had a return on equity of 11.94% and a net margin of 37.88%. View Taro Pharmaceutical Industries' earnings history.

What price target have analysts set for TARO?

1 equities research analysts have issued 12-month target prices for Taro Pharmaceutical Industries' shares. Their forecasts range from $96.00 to $96.00. On average, they expect Taro Pharmaceutical Industries' share price to reach $96.00 in the next year. This suggests a possible upside of 41.1% from the stock's current price. View analysts' price targets for Taro Pharmaceutical Industries.

Has Taro Pharmaceutical Industries been receiving favorable news coverage?

News articles about TARO stock have been trending somewhat positive on Friday, according to InfoTrie. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Taro Pharmaceutical Industries earned a news sentiment score of 1.6 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutTaro Pharmaceutical Industries.

Are investors shorting Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries saw a drop in short interest in the month of April. As of April 30th, there was short interest totaling 131,900 shares, a drop of 13.0% from the April 15th total of 151,600 shares. Based on an average daily volume of 49,900 shares, the days-to-cover ratio is presently 2.6 days. Approximately 1.5% of the company's shares are short sold. View Taro Pharmaceutical Industries' Current Options Chain.

Who are some of Taro Pharmaceutical Industries' key competitors?

What other stocks do shareholders of Taro Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Taro Pharmaceutical Industries investors own include Gilead Sciences (GILD), Broadcom (AVGO), Bausch Health Companies (BHC), Pfizer (PFE), Teva Pharmaceutical Industries (TEVA), Skyworks Solutions (SWKS), GW Pharmaceuticals PLC- (GWPH), Jazz Pharmaceuticals (JAZZ), Mallinckrodt (MNK) and Novo Nordisk A/S (NVO).

Who are Taro Pharmaceutical Industries' key executives?

Taro Pharmaceutical Industries' management team includes the following people:
  • Mr. Uday V. Baldota, CEO & Director (Age 49)
  • Mr. Mariano Balaguer, CFO, Chief Accounting Officer & VP (Age 46)
  • Mr. Itamar Karsenti, VP & Head of Global Operations (Age 47)
  • Mr. Itzik Baruch, VP of Technical Services (Age 56)
  • Dr. Roman Kaplan Ph.D., VP of Scientific and Technical Compliance Mang. (Age 72)

What is Taro Pharmaceutical Industries' stock symbol?

Taro Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TARO."

Who are Taro Pharmaceutical Industries' major shareholders?

Taro Pharmaceutical Industries' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Krensavage Asset Management LLC (1.27%), Acadian Asset Management LLC (0.92%), APG Asset Management N.V. (0.57%), Invesco Ltd. (0.40%), APG Asset Management N.V. (0.34%) and APG Asset Management N.V. (0.34%).

Which institutional investors are selling Taro Pharmaceutical Industries stock?

TARO stock was sold by a variety of institutional investors in the last quarter, including APG Asset Management N.V., APG Asset Management N.V., Invesco Ltd., Bank of New York Mellon Corp, JPMorgan Chase & Co., Parametric Portfolio Associates LLC, Jane Street Group LLC, and CLARET ASSET MANAGEMENT Corp.

Which institutional investors are buying Taro Pharmaceutical Industries stock?

TARO stock was bought by a variety of institutional investors in the last quarter, including Krensavage Asset Management LLC, Citigroup Inc., Acadian Asset Management LLC, AXA, Deutsche Bank AG, APG Asset Management N.V., Morgan Stanley, and Empirical Finance LLC.

How do I buy shares of Taro Pharmaceutical Industries?

Shares of TARO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Taro Pharmaceutical Industries' stock price today?

One share of TARO stock can currently be purchased for approximately $68.03.

How big of a company is Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries has a market capitalization of $2.60 billion and generates $644.77 million in revenue each year. The company earns $244.24 million in net income (profit) each year or $6.35 on an earnings per share basis. Taro Pharmaceutical Industries employs 1,464 workers across the globe.

What is Taro Pharmaceutical Industries' official website?

The official website for Taro Pharmaceutical Industries is www.taro.com.

How can I contact Taro Pharmaceutical Industries?

Taro Pharmaceutical Industries' mailing address is 14 HAKITOR ST PO BOX 10347, HAIFA BAY L3, 10532. The company can be reached via phone at 972-4847-5700 or via email at [email protected]

This page was last updated on 6/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.